Navigation Links
Off-Label Use of Clotting Drug Soars, Report Finds
Date:4/18/2011

MONDAY, April 18 (HealthDay News) -- Hospitals are using a pricey blood-clotting drug in treating people who do not have hemophilia, a rare disorder in which blood does not clot normally -- even though its use in such patients is potentially risky, according to new research.

Stanford University researchers found that use of the drug, known as recombinant factor 7a, grew by 140 times from use in 125 cases in 2000 to 17,813 in 2008, with off-label uses accounting for most of the increase.

The $10,000-a-dose drug was used in people with hemophilia just 4 percent of the time, according to U.S. hospital statistics from 2000 to 2008. The rest of the time, it was used during heart surgery and to treat medical problems such as trauma and bleeding in the brain. The researchers content that such use puts patients at risk for heart attack and stroke because the drug can boost the risk of blood clots.

"The stakes are high with this one," Dr. Veronica Yank, an instructor in medicine at Stanford and the first author of one of two new studies on the drug, said in a university news release. "Because it's such a powerful clotting agent, it has the potential when used off-label to damage the lives of patients without providing any real benefit."

Yank and her colleagues said that physicians should be more cautious with the drug until there's more research into whether it's appropriate to use in certain cases.

The studies, published April 19 in Annals of Internal Medicine, are accompanied by a commentary from Harvard Medical School researchers, which says the research provides "compelling data about the runaway use, uselessness and risk for this expensive treatment."

The studies were funded by the U.S. Agency for Healthcare Quality and Research after previous research raised concerns that RF7a increased the risk for blood clots. The agency asked for an assessment of five off-label uses of RF7a: heart surgery, int
'/>"/>

Copyright©2010 ScoutNews,LLC.
All rights reserved  

Page: 1 2

Related medicine news :

1. Hemophilia Drug Used Off-Label Raises Clot Risk
2. Anti-clotting agent does not improve outcomes of patients with severe pneumonia
3. New Anti-Clotting Drug May Work Better After Hip Replacement
4. Extended use of anti-clotting drug helps some bedridden patients
5. Tests to Measure Safety of Anti-Clotting Drugs of Limited Value
6. TBI Therapy and Nutrition: IOM report releases April 20
7. Boston University researchers find most substance-dependent individuals report poor oral health
8. Making temporary changes to brain could speed up learning, study reports
9. Aerobic Exercise May Curb Non-Alcoholic Fatty Liver Disease: Report
10. Brisk Walk Can Boost Blood Flow to the Brain: Report
11. U.S. Reports Drop in AIDS-Related Cancers
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Off-Label Use of  Clotting Drug Soars, Report Finds
(Date:7/22/2014)... Aaron Marshall, Corporate Counsel at Northrop Grumman, will ... Agency for the 2014-2015 fiscal year. He joined the ... states, "“Serving on the HASA board has given me a ... me remember how much others need help." , ABOUT AARON ... has a B.S. in Finance from the University of Delaware. ...
(Date:7/22/2014)... Society of Hematology (ASH) will honor Tomas Ganz, MD, ... with the 2014 E. Donnall Thomas Lecture for his ... the iron-regulatory hormone hepcidin and investigation of its roles ... Prize Laureate and past Society president E. Donnall Thomas, ... represented a paradigm shift or significant discovery in the ...
(Date:7/22/2014)... at the University of Utah,s John A. Moran Eye ... Eye Research (ISER) as the recipient of the Houston, ... in Retina Research., The award recognizes lifetime achievement by ... to the understanding of vitreoretinal diseases or disorders. The ... Biennial Meeting in San Francisco, where Marc will deliver ...
(Date:7/22/2014)... As reported on July 17, 2014 by ABC News, ... favorite beauty products, “ Botox , that’s pretty much it.” ... has changed my life” by halving the amount of ... various, daily appearances. “Suddenly my eyelids are no longer ... “I think that Kelly Ripa’s response to the question was ...
(Date:7/22/2014)... American Conference on Lung Cancer (LALCA 2014) will be ... , Lung Cancer is still the leading cause of ... on the success of the previous conferences in Chile, ... discuss the science and advances in the treatment and ... Latin America in particular. , With tobacco being the ...
Breaking Medicine News(10 mins):Health News:New Board President for Baltimore-based Nonprofit 2Health News:Tomas Ganz, M.D., Ph.D., to present 2014 ASH E. Donnall Thomas Lecture 2Health News:Tomas Ganz, M.D., Ph.D., to present 2014 ASH E. Donnall Thomas Lecture 3Health News:University of Utah researcher Robert Marc receives Paul Kayser International Award 2Health News:Celebrity Botox: Kelly Ripa Confesses to Getting Botox Injections 2
... Dr. Lawyer will lead clinical efforts of the ... KePRO, a national medical,management firm, appointed Lenaye ... Dr. Lawyer will oversee all clinical aspects of ... Harrisburg,office., "Dr. Lawyer has practiced her entire ...
... the Northeast region with more hires,planned throughout the ... Aug. 28 The Pennsylvania,Patient Safety Authority has ... to help healthcare facilities that report to the,Pennsylvania ... Pennsylvania citizens., "Last year in focus groups ...
... 67%, but patients and doctors say drug is hard to ... percent of patients with atrial fibrillation, a known risk factor ... anti-clotting drug warfarin, a new study found. , Among those ... prevent a stroke. And an additional 25 percent were taking ...
... growing professional and consumer markets in China. , ... ... international venture capital firm, today announced that together with Mustang Ventures, ... of financing for Profex.Inc. Trident Capital & Mustang Ventures jointly invested ...
... HAYWARD, Calif., Aug. 28 Guava Technologies, Inc.,announced ... Group to,provide drug discovery researchers with an automated ... key component of a larger,strategic initiative by Guava ... voiced need for sophisticated cell analysis technology to,support ...
... increased plaque , , THURSDAY, Aug. 28 (HealthDay News) -- A ... in the brain that is thought to play a key ... the protein, known as amyloid beta, was directly linked to ... When brain cell communication increased, so did amyloid beta. When ...
Cached Medicine News:Health News:Lenaye Lawyer, MD, FACOG, Named KePRO Medical Director 2Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 2Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 3Health News:Most Patients With Irregular Heartbeat Take Inadequate Blood Thinner Dose 2Health News:Most Patients With Irregular Heartbeat Take Inadequate Blood Thinner Dose 3Health News:Trident Capital and Mustang Ventures Lead Series A Investment in Profex, Inc. 2Health News:Trident Capital and Mustang Ventures Lead Series A Investment in Profex, Inc. 3Health News:San Francisco Bay Area Cell Analysis Company Forges Partnership With Hudson Control Group as First Step in Automation Initiative to Support Drug Discovery Research 2Health News:San Francisco Bay Area Cell Analysis Company Forges Partnership With Hudson Control Group as First Step in Automation Initiative to Support Drug Discovery Research 3Health News:Scientists Track Hourly Changes in Alzheimer's Protein 2
(Date:7/22/2014)... , July 22, 2014  Neurotrope Bioscience, Inc., ... a world-wide, exclusive license agreement with the Icahn School ... ( Mount Sinai ) to utilize its ... Bryostatin-1 in the treatment of Niemann-Pick Type C Disease ... afflicted with Alzheimer-like symptoms. The license also covers other ...
(Date:7/22/2014)... , July 22, 2014 WuXi PharmaTech (Cayman) ... and medical device R&D outsourcing company with operations in ... , today announced that it will release financial results ... Stock Exchange closes on Wednesday, August 13, 2014 (which will ... release will be available on the investor relations section of ...
(Date:7/22/2014)... July 22, 2014  UL (Underwriters Laboratories), a ... U.S. Food and Drug Administration (FDA) has recognized ... for medical devices incorporating lithium or nickel-based batteries. ... for Household and Commercial Batteries, and UL 1642 ... Consensus standards are standards recognized by the ...
Breaking Medicine Technology:Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 2Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 3Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 4Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 5WuXi PharmaTech Schedules Second-Quarter 2014 Earnings Release 2Two UL Battery Safety Standards Are now FDA Recognized Consensus Standards for Medical Devices 2
... 6, 2011 A new study , released ... the United States witnessed opiate prescriptions for chronic abdominal ... Michael Lowenstein, co-medical director for the Waismann Method, an ... that this increase signals the gaining popularity of prescription ...
...  Glowpoint, Inc. (OTCBB: GLOW), a leading global provider of ... a leading global pharmaceutical services company has signed with ...   This new Glowpoint customer is the ... clinical, commercial, consulting and capital solutions. The firm has ...
Cached Medicine Technology:Rise in Opioid Use for Abdominal Pain Points to Larger Problem Warns Waismann Method Medical Director 2Rise in Opioid Use for Abdominal Pain Points to Larger Problem Warns Waismann Method Medical Director 3Global Pharmaceutical Services Company Turns to Glowpoint's OpenVideo™ Cloud 2
... The new Finnpipette Focus ... specifically to combine ergonomics with ... interchangeable handle plate offers a ... sizes. The new shorter tip ...
Inquire...
Pipetman F is a fixed-volume, air-displacement pipette. Thirteen robust models cover a large volume range from 2 L to 1000 L, with Gilsons legendary accuracy and precision....
Pipetman F is a fixed-volume, air-displacement pipette. Thirteen robust models cover a large volume range from 2 L to 1000 L, with Gilsons legendary accuracy and precision....
Medicine Products: